1. Home
  2. TLF vs AKTX Comparison

TLF vs AKTX Comparison

Compare TLF & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tandy Leather Factory Inc.

TLF

Tandy Leather Factory Inc.

N/A

Current Price

$2.64

Market Cap

19.5M

ML Signal

N/A

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

N/A

Current Price

$8.01

Market Cap

18.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TLF
AKTX
Founded
1980
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.5M
18.2M
IPO Year
2006
2014

Fundamental Metrics

Financial Performance
Metric
TLF
AKTX
Price
$2.64
$8.01
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$33.50
AVG Volume (30 Days)
24.6K
32.7K
Earning Date
05-11-2026
05-14-2026
Dividend Yield
32.05%
N/A
EPS Growth
1122.22
N/A
EPS
0.08
N/A
Revenue
$76,324,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$32.38
N/A
Revenue Growth
2.60
N/A
52 Week Low
$2.20
$0.12
52 Week High
$3.36
$29.32

Technical Indicators

Market Signals
Indicator
TLF
AKTX
Relative Strength Index (RSI) 69.55 44.01
Support Level $2.27 $0.21
Resistance Level $2.75 $15.50
Average True Range (ATR) 0.09 0.73
MACD 0.02 0.17
Stochastic Oscillator 66.27 84.28

Price Performance

Historical Comparison
TLF
AKTX

About TLF Tandy Leather Factory Inc.

Tandy Leather Factory Inc is a specialty retailers of leather and leathercraft-related items. Its primary line of business is the sale of leather, leather crafts, and related supplies. Its broad line of leather and related products includes leather, leatherworking tools, leather dyes and finishes, and do-it-yourself kits. Its products include Leather, tools, Hardware, Supplies, Kits, Books and Patterns, and Gift cards. The company sells its products primarily through company-owned stores and through orders generated from its global websites, and through direct account representatives in its commercial division. Geographically the company operates within the United States, and Canada. it generates the highest revenue from the United States.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Share on Social Networks: